Jacqualyn A Fouse - Net Worth and Insider Trading

Jacqualyn A Fouse Net Worth

The estimated net worth of Jacqualyn A Fouse is at least $3 Million dollars as of 2023-06-08. Jacqualyn A Fouse is the see remarks of Celgene Corp and owns about 18,664 shares of Celgene Corp (CELG) stock worth over $2 Million. Jacqualyn A Fouse is also the CEO of Agios Pharmaceuticals Inc and owns about 41,722 shares of Agios Pharmaceuticals Inc (AGIO) stock worth over $1 Million. Details can be seen in Jacqualyn A Fouse's Latest Holdings Summary section.

Transaction Summary of Jacqualyn A Fouse

To

Jacqualyn A Fouse Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jacqualyn A Fouse owns 5 companies in total, including Incyte Corp (INCY) , Dick's Sporting Goods Inc (DKS) , and Bunge Ltd (BG) among others .

Click here to see the complete history of Jacqualyn A Fouse’s form 4 insider trades.

Insider Ownership Summary of Jacqualyn A Fouse

Ticker Comapny Transaction Date Type of Owner
INCY Incyte Corp 2017-11-14 director
DKS Dick's Sporting Goods Inc 2014-04-03 director
BG Bunge Ltd 2009-09-02 Chief Financial Officer
AGIO Agios Pharmaceuticals Inc 2017-12-03 director
PRGO Perrigo Co PLC 2013-12-18 director

Jacqualyn A Fouse Latest Holdings Summary

Jacqualyn A Fouse currently owns a total of 2 stocks. Among these stocks, Jacqualyn A Fouse owns 18,664 shares of Celgene Corp (CELG) as of May 21, 2012, with a value of $2 Million and a weighting of 64.18000000000001%. Jacqualyn A Fouse also owns 41,722 shares of Agios Pharmaceuticals Inc (AGIO) as of November 13, 2019, with a value of $1 Million and a weighting of 35.82%.

Latest Holdings of Jacqualyn A Fouse

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
CELG Celgene Corp 2012-05-21 18,664 108.24 2,020,191
AGIO Agios Pharmaceuticals Inc 2019-11-13 41,722 27.03 1,127,746

Holding Weightings of Jacqualyn A Fouse


Jacqualyn A Fouse Form 4 Trading Tracker

According to the SEC Form 4 filings, Jacqualyn A Fouse has made a total of 0 transactions in Celgene Corp (CELG) over the past 5 years. The most-recent trade in Celgene Corp is the acquisition of 2,000 shares on May 21, 2012, which cost Jacqualyn A Fouse around $68,920.

According to the SEC Form 4 filings, Jacqualyn A Fouse has made a total of 1 transactions in Agios Pharmaceuticals Inc (AGIO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Agios Pharmaceuticals Inc is the acquisition of 40,322 shares on November 13, 2019, which cost Jacqualyn A Fouse around $1 Million.

Insider Trading History of Jacqualyn A Fouse

Ticker
Company
Date
Buy/Sell
Insider Trading Shares
Shares Change
Price
Cost
Final Share
Current Price
Price Change Since Insider Trade (%)
Filing Date
AGIO
Agios Pharmaceuticals Inc
2019-11-13
Buy
40,322.00
2,880.14%
$31.00
$1,249,980.00
41,722.00
$27.03
-12.81%
-
DELISTED:CELG
Celgene Corp
2012-05-21
Buy
2,000.00
27.28%
$34.46
$68,920.00
18,664.00
$108.24
214.10%
-
DELISTED:CELG
Celgene Corp
2011-11-01
Buy
2,000.00
32.87%
$31.96
$63,920.00
16,170.00
$108.24
238.67%
-
DELISTED:CELG
Celgene Corp
2011-08-09
Buy
2,000.00
39.33%
$27.07
$54,130.00
14,170.00
$108.24
299.93%
-
DELISTED:CELG
Celgene Corp
2011-08-05
Buy
2,000.00
48.96%
$27.88
$55,750.00
12,170.00
$108.24
288.30%
-
DELISTED:CELG
Celgene Corp
2011-08-01
Buy
4,000.00
368.66%
$29.73
$118,940.00
10,170.00
$108.24
264.02%
-
DELISTED:CELG
Celgene Corp
2011-06-14
Buy
4,000.00
0%
$29.13
$116,520.00
6,170.00
$108.24
271.58%
-
Total 7
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jacqualyn A Fouse Trading Performance

GuruFocus tracks the stock performance after each of Jacqualyn A Fouse's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jacqualyn A Fouse is 16.53%. GuruFocus also compares Jacqualyn A Fouse's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jacqualyn A Fouse within 3 months outperforms 6 times out of 7 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jacqualyn A Fouse's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jacqualyn A Fouse

Average Relative Return

28.83%

Average relative return per transaction

Outperforming Transactions

100%

7 out of 7 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) 5.88 16.53 22.55 28.83 48.2 38.73
Relative Return to S&P 500(%) 6.34 13.47 17.32 13.77 29.64 23.21

Jacqualyn A Fouse Ownership Network

Ownership Network List of Jacqualyn A Fouse

No Data

Ownership Network Relation of Jacqualyn A Fouse


Jacqualyn A Fouse Owned Company Details

What does Incyte Corp do?

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Who are the key executives at Incyte Corp?

Jacqualyn A Fouse is the director of Incyte Corp. Other key executives at Incyte Corp include Principal Accounting Officer Thomas Tray , EVP & Head of Tech. Operations Michael James Morrissey , and EVP & General Manager & Europe Jonathan Elliott Dickinson .

Incyte Corp (INCY) Insider Trades Summary

Over the past 18 months, Jacqualyn A Fouse made no insider transaction in Incyte Corp (INCY). Other recent insider transactions involving Incyte Corp (INCY) include a net purchase of 2,510,403 shares made by Baker Bros. Advisors Lp , a net sale of 30,111 shares made by Vijay K Iyengar , and a net sale of 46,866 shares made by Barry P Flannelly .

In summary, during the past 3 months, insiders sold 0 shares of Incyte Corp (INCY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 208,851 shares of Incyte Corp (INCY) were sold and 2,510,403 shares were bought by its insiders, resulting in a net purchase of 2,301,552 shares.

Incyte Corp (INCY)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Incyte Corp Insider Transactions

No Available Data

Jacqualyn A Fouse Mailing Address

Above is the net worth, insider trading, and ownership report for Jacqualyn A Fouse. You might contact Jacqualyn A Fouse via mailing address: C/o Dick's Sporting Goods, 345 Court Street, Coraopolis Pa 15108.